KRAS and lung cancer: Given the in vitro and in vivo data pointing to a role of UHRF1 in KRAS-driven lung cancer, we hypothesized that human lung cancer patients with elevated UHRF1 levels may have a worse prognosis than patients with low UHRF1 expression.